PMID- 32375443
OWN - NLM
STAT- MEDLINE
DCOM- 20200717
LR  - 20211204
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 100
IP  - 17
DP  - 2020 May 5
TI  - [Effect of mammalian target of rapamycin on cognitive dysfunction of Alzheimer's 
      Disease via regulating Homer3].
PG  - 1336-1340
LID - 10.3760/cma.j.cn112137-20191108-02437 [doi]
AB  - Objective: To exploer the effect of mammalian target ofrapamycin(mTOR)on 
      cognitive dysfunction of mice with Alzheimer's disease (AD) induced by amyloid 
      beta(1-42) (Abeta(1-42)) via observing the regulation effect of rapamycin on Homer3 in 
      hippocampus. Methods: The 32 mice were randomly divided into fourgroups: sham 
      group (the hippocampus of mice was injected with normal saline); AD group (the 
      hippocampus of mice was injected with Abeta(1-42)); DMSO group(AD mice induced by 
      Abeta(1-42) were intraperitoneally injected with dimethylsulfoxide for 14 days);RAPA 
      group(AD mice induced by Abeta(1-42) were intraperitoneally injected with rapamycin 
      1 mg/kg for 14 days). Morris maze and Y maze experiments to measuring cognitive 
      function and immunowestern bloting detecting the expression of Abeta(1-42), mTOR, 
      p-mTOR and Homer3 in the hippocampus were conducted on each group of mice. 
      Results: Compared with sham group,the AD group showed significantly longer escape 
      latency,shoter residence time of objective quadrant, less numbers of crossing of 
      original platform, lower alternation ratio(P<0.05); Compared with DMSO group, 
      RAPA group showed significantly shorter escape latency, longer residence time of 
      objective quadrant, more numbers of crossing of original platform, more 
      alternation ratio(P<0.05). The levels of Abeta(1-42) and p-mTOR were increased, the 
      levels of Homer3 were decreased in DMSO group mice's hippocampus compared with 
      sham group(P<0.05); the levels of Abeta(1-42) and p-mTOR were decreased,the levels 
      of Homer3 were increased in RAPA group mice's hippocampus compared with DMSO 
      group(P<0.05). Conclusion: The inhibitor of mTOR rapamycin can improve the 
      cognitive dysfunction of mice with AD induced by Abeta(1-42) and reduce deposition 
      of Abeta(1-42) in the hippocampus, and the possible mechanism is rapamycin 
      depressing the phosphorylation of mTOR as the same as Up-regulation the 
      expression level of Homer3.
FAU - Huang, Y Q
AU  - Huang YQ
AD  - Department of Anesthesiology, Affiliated Hangzhou First People's Hospital, 
      Zhejiang University School of Medicine,Hangzhou 310006,China.
FAU - Liu, X G
AU  - Liu XG
AD  - Department of Anesthesiology, the Second Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou 325027, China.
FAU - Zhang, L
AU  - Zhang L
AD  - the Fourth Clinical College of Zhejiang Chinese Medical University, Hangzhou 
      310053, China.
FAU - Yu, Y
AU  - Yu Y
AD  - the Fourth Clinical College of Zhejiang Chinese Medical University, Hangzhou 
      310053, China.
FAU - Xue, J
AU  - Xue J
AD  - the Fourth Clinical College of Zhejiang Chinese Medical University, Hangzhou 
      310053, China.
FAU - Sun, J L
AU  - Sun JL
AD  - Department of Anesthesiology, the Second Affiliated Hospital of Wenzhou Medical 
      University, Wenzhou 325027, China.
LA  - chi
GR  - LY17C090002/Zhejiang Provincial Natural Science Foundation/
GR  - 20170533B32/Social Development Project of Hangzhou Science And Technology 
      Commission/
GR  - 2017KY520/Medical Health Research Program of Zhejiang Province/
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Amyloid beta-Peptides)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - *Alzheimer Disease
MH  - Amyloid beta-Peptides
MH  - Animals
MH  - *Cognitive Dysfunction
MH  - Disease Models, Animal
MH  - Hippocampus
MH  - Mice
MH  - Sirolimus
MH  - TOR Serine-Threonine Kinases
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Amyloid beta(1-42)
OT  - Mammalian target ofrapamycin
OT  - Phosphorylate-mammalian target of rapamycin
OT  - Rapamycin
EDAT- 2020/05/08 06:00
MHDA- 2020/07/18 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2020/07/18 06:00 [medline]
AID - 10.3760/cma.j.cn112137-20191108-02437 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2020 May 5;100(17):1336-1340. doi: 
      10.3760/cma.j.cn112137-20191108-02437.